Review Article
Visfatin/Nampt: An Adipokine with Cardiovascular Impact
Table 1
Summary of the main correlations reported between visfatin circulating levels and CV disease in human subjects.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
: no change in circulating visfatin levels. : enhanced circulating visfatin levels. : reduced circulating visfatin levels. +: positive correlation reported, −: negative correlation reported, ±: no significant correlation reported. CAD: coronary artery disease, FMD: flow-mediated dilation, GFR: glomerular filtration rate, hsCRP: high-sensitivity C-reactive protein, IL: interleukin, IMT: intima-media thickness, IRA: infarct-related artery, LDLc: low-density lipoprotein-associated cholesterol, MCAM: melanoma cell adhesion molecule, MCP-1: monocyte chemotactic protein-1, PAI-1: plasminogen activator inhibitor-1, PCOS: polycystic ovary syndrome, sICAM: soluble intercellular adhesion molecule, sVCAM: soluble vascular cell adhesion molecule, and TD2: type 2 diabetes mellitus. |